| LYRIC/AEG1, also known as astrocyte elevated gene‑1 or metadherin (MTDH), is a multifunctional protein encoded by the MTDH gene that localizes to the endoplasmic reticulum, perinuclear region and nucleus, and acts as a scaffold and adaptor in signaling and transcriptional networks that drive oncogenesis, metastasis and therapy resistance. The protein is lysine-rich and predicted to contain transmembrane and coiled-coil segments that facilitate membrane association and protein–protein interactions, allowing LYRIC/AEG1 to assemble complexes with signaling molecules and transcriptional regulators rather than functioning as a classical enzyme. In hepatocellular carcinoma, LYRIC/AEG1 is markedly upregulated and shown by gain- and loss-of-function studies to positively regulate multiple hallmarks of HCC progression, including proliferation, angiogenesis, invasion and metastasis; genetic deletion of AEG‑1 in mice prevents DEN-induced hepatocarcinogenesis by blocking NF‑κB activation, dampening inflammatory and survival gene expression and reducing tumor burden, indicating that LYRIC/AEG1 is required for carcinogen-driven liver tumor initiation and progression. Mechanistically, LYRIC/AEG1 activates several pathways relevant to HCC, including NF‑κB, PI3K/Akt and Wnt/β‑catenin signaling: overexpression enhances NF‑κB nuclear activity and upregulates angiogenesis- and chemoresistance-associated genes, and clinical studies link high AEG‑1 expression with increased β‑catenin, c‑Myc and cyclin D1, supporting a role in transcriptional activation of proliferative and stemness programs. LYRIC/AEG1 also influences autophagy and apoptosis, and contributes to chemoresistance by upregulating MDR genes and survival pathways, so its expression level predicts response to chemotherapy and correlates with poor prognosis in HCC cohorts. In breast cancer, AEG‑1/MTDH/LYRIC is a key functional target of recurrent 8q22 genomic gain seen in poor‑prognosis tumors, where it plays a dual role in promoting metastasis and chemoresistance; overexpression enhances tumor cell proliferation, adhesion, invasion, angiogenesis and survival under cytotoxic stress, while knockdown reduces metastatic spread and sensitizes cells to chemotherapeutic agents in xenograft models. Across multiple cancer types, clinicopathologic studies consistently show that high LYRIC/AEG1 expression associates with advanced stage, high-grade histology, increased microvessel density and hematogenous metastasis, and serum anti-AEG‑1 antibody titers can serve as predictors of aggressive disease, highlighting its potential as both tissue and blood-based biomarker. These data, together with evidence that LYRIC/AEG1 sits at the intersection of NF‑κB, PI3K/Akt, Wnt/β‑catenin and autophagy pathways and orchestrates gene-expression changes underlying proliferation, invasion, angiogenesis and chemoresistance, define LYRIC/AEG1 as a structurally adaptable and mechanistically central oncogenic regulator that is highly relevant for researchers evaluating signaling-driven tumor biology and exploring targeted interventions in liver, breast and other cancers. |
